RxDoctor Payments Data

Xiangsheng Zheng, MD

Internal Medicine · Birmingham, ALNPI 1396861332

Payments from drug & device makers

$9,668in general payments, 2019–2025

Across 99 payments — averaging $97.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$7K
  • Bayer$784
  • Boehringer Ingelheim$459
  • Amarin Pharma, Inc.$406
  • Kowa Pharmaceuticals America, Inc.$365
  • Madrigal Pharmaceuticals$132
  • plus $395 from 5 others

What the payments were for

  • Consulting fees$6,27765%
  • Travel & lodging$6577%
  • Food & beverage$2,68928%
  • Education$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,668 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$5,798
Medicare patients
15
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Epolamine2,978$2,175,567
VascepaIcosapent Ethyl2,851$1,016,082
RestasisCyclosporine1,421$920,571
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate757$893,200
JanuviaSitagliptin Phosphate1,101$634,431
Diclofenac Sodium877$565,168
CreonLipase/Protease/Amylase299$371,891
RybelsusSemaglutide349$344,075
VemlidyTenofovir Alafenamide223$315,742
Clobetasol Propionate1,443$249,772
LinzessLinaclotide406$214,714
Dexlansoprazole DrDexlansoprazole1,006$158,749
Combivent RespimatIpratropium/Albuterol Sulfate299$141,899
Lactulose76$141,307
Halobetasol Propionate1,296$110,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Creon, Linzess, Synthroid$103$1,532,7212,618 claims
Boehringer IngelheimCombivent Respimat, Jardiance, Tradjenta$459$262,050494 claims
BayerKerendia$784$103,453151 claims
Lilly USA, LLCTrulicity$109$37,58926 claims
Aimmune Therapeutics, Inc.Zenpep$37$31,84042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →